NCT07331155 2026-03-09
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Recruiting
Nanjing Leads Biolabs Co.,Ltd
Genmab
Astellas Pharma Inc
Akeso
Mirati Therapeutics Inc.
Merck Sharp & Dohme LLC
CStone Pharmaceuticals
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
EMD Serono
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Qilu Pharmaceutical Co., Ltd.
M.D. Anderson Cancer Center
BeiGene
Providence Health & Services
UCB Pharma